What You Should Know:
– Outpace Bio, a pioneering cell therapy company raises $144M in oversubscribed Series B financing round led by RA Capital Management with participation from both new and existing investors, including Qatar Investment Authority, Surveyor Capital, Sheatree Capital, Black Opal Ventures, Alexandria Venture Investments, and several others. Outpace has now raised a total of approximately $200M to date.
– Jake Simson, Partner at RA Capital Management, will join Outpace Bio’s Board of Directors.
Transforming Cancer Treatment with AI-Powered Cell Therapy
Outpace Bio is focused on revolutionizing cancer treatment through its AI-powered protein design platform. The company’s proprietary technology enables the creation of engineered T cells with enhanced capabilities, such as improved tumor infiltration, extended persistence, and resistance to immune suppression.
The lead product candidate, OPB-101, a mesothelin-specific CAR T cell therapy, is on track to enter clinical trials in 2025 for the treatment of ovarian cancer. Outpace’s platform is designed to be adaptable to various cancer types, enabling the company to rapidly expand its pipeline. The funds will be used to accelerate the development of its innovative cell therapy platform and advance multiple product candidates into clinical trials.
“We are grateful for the support and partnership of an outstanding syndicate of top-tier investors who share our vision,” said Marc Lajoie, PhD, Co-Founder & Chief Executive Officer of Outpace. “At our founding we set out to build groundbreaking technologies that access novel biology unreachable by standard protein engineering approaches, allowing us to program how cell therapies function inside patients: to access the tumor, to survive / expand / functionally persist in the tumor, and to broaden the host immune response in the tumor microenvironment. This Series B financing allows us to accelerate the clinical development of our first two programs and to expand our innovative pipeline & platform as we aim to change patient outcomes for the better.”
